control group:camrelizumab

3 trials

Sponsors

The Affiliated Hospital of Qingdao University, The Third Affiliated Hospital of Shandong First Medical University, The First Affiliated Hospital of Zhengzhou University

Conditions

Colorectal cancerLung cancerrectal cancer

Early Phase 1

A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer

RecruitingChiCTR2100053040

The Affiliated Hospital of Qingdao UniversityColorectal cancer

Start: 2021-12-01Updated: 2022-09-06

A controlled and open clinical study of effect of hydrogen inhalation on camrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer

RecruitingChiCTR2100053330

The Third Affiliated Hospital of Shandong First Medical UniversityLung cancer

Start: 2021-11-22Updated: 2022-10-17

Phase 4

Clinical Trial of Short Range Radiotherapy Sequential Camrelizumab ± CAPOX Neoadjuvant Therapy for Locally Advanced Rectal Cancer

RecruitingChiCTR2300072471

The First Affiliated Hospital of Zhengzhou Universityrectal cancer

Start: 2022-01-30Updated: 2023-06-18

Related Papers

Efficacy and safety of camrelizumab and apatinib combined with neoadjuvant concurrent chemoradiation for MSS locally advanced rectal cancer.

Journal of Clinical Oncology2023-06-011 citations